You have no items in your cart.
Fewer HAE Attacks Evident With Takhzyro Use in Canadian Study
Angioedema News
Use of Takhzyro (lanadelumab) for at least six months led to fewer hereditary angioedema (HAE) attacks and treated attacks, a case review study from Canada reported. Three of its 12 patients ... Read more